STUDY | **Ruxolitinib versus basiliximab in adult patients with steroid-refractory aGvHD**

Population: N = 129

Primary endpoints: OR at Day 28, including CR and PR; DOR at Day 56; cumulative incidence of cGvHD at 1 year; OS at 1 year; cumulative incidence of FFS at 1 year; median OS and FFS

Eligibility: Adult patients with SR-aGvHD

TRIAL DESIGN

Drug 1 Ruxolitinib	Drug 2 Ruxolitinib	Drug 3 Basiliximab
5 mg/bid (if platelet count is 20 × 109/L)	**10 mg/bid** (If platelet count is > 30 × 10^9/L)	**20 mg once** Days 1, 4, 8, 15, and 21.
for 3 years	**for 0–3 years**	**for 21 days**

Ruxolitinib
Basiliximab

EFFICACY

Response rates

ORR	CR	DOR at Day 56	aGvHD OR (Grade I–II)	aGvHD OR (Grade III–IV)
72.8%	58.0%	63.0%	79.4%	68.1%
54.2%	35.4%	52.1%	78.6%	44.1%



FFS cumulative incidence





Median OS

Ruxolitinib
Basiliximab

SAFETY

Cumulative incidences of cGvHD at 1 year



p = 0.021

Occurrence of cGvHD was lower in patients in the ruxolitinib group in the liver (p = 0.005) and joints (p = 0.020).

Ruxolitinib showed favorable results in the treatment of SR-aGvHD and reduced the incidence of cGvHD compared with basiliximab.

Abbreviations: aGvHD, acute graft-versus-host disease; bid, twice a day; cGvHD, chronic GvHD; CR, complete response; DOR, duration of response; FFS, failure-free survival; OR, overall response; OS, overall survival; PR, partial response; SR-aGvHD, steroid-refractory aGvHD.

Lui, et al. *Ann Hematol.* 2023;102(10):2865-2877. DOI: 10.1007/s00277-023-05361-9

GvHDHub | Brought to you by Scientific Education Support

This educational resource is supported through funds from pharmaceutical companies; a full list of our supporters can be found at gvhdhub.com. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.